详情页 - 首都医科大学附属北京同仁医院知识库

当前位置：首页 > 详情页

Very-Low-Dose Decitabine Is Effective in Treating Intermediate- or High-Risk Myelodysplastic Syndrome

文献详情

资源类型：

WOS体系：

收录情况： ◇ SCIE

作者：

机构： [1]Fu-Xing Hospital, [2]Xuanwu Hospital, [3]Beijing Friendship Hospital, Capital Medical College, [4]The 309th Military Hospital of Chinese People’s Liberation Army, affiliated to Capital Medical College, [5]Beijing Chao-Yang Hospital, [6]First Affiliated Hospital of PLA General Hospital, [7]Beijing Chuiyangliu Hospital, [8]Beijing Tsinghua Changgung Hospital, [9]Beijing Hospital, [10]Beijing Tongren Hospital, [11]Chinese People’s Liberation Army Rocket Army Hospital, [12]PLA Army General Hospital, [13]Beijing Aerospace Center Hospital, [14]Peking Union Medical College Hospital, Beijing , China

出处：

DOI：

ISSN：

关键词： Myelodysplastic syndrome Decitabine Very low dose Efficacy Cost

摘要：

Nowadays, the regular recommended dose of decitabine for the treatment of myelodysplastic syndrome (MDS) is 20 mg/m(2)/day for 5 consecutive days with a relatively high incidence of treatment-related morbidities and costs. In this study, a retrospective and multicenter analysis was performed to explore the very-low-dose decitabine schedule for the treatment of patients with IPSS intermediate-or high-risk MDS. A total of 31 newly diagnosed MDS cases from 14 hospitals in Beijing received decitabine monotherapy (decitabine 6 mg/m(2)/day intravenously for 7 consecutive days, repeated every 4 weeks). With a medium follow-up of 4 months, 10 patients achieved complete remission (32.3%), 8 (25.8%) partial remission, and 3 (9.7%) hematological improvement. The overall response rate (ORR) was 67.7%. Rates of 21.7% for severe infections and 11.6% for severe bleedings were observed among all courses. The median cost of each course was USD 5,300, 3,000, 2,900, and 2,000, respectively. Multivariate analysis identified bone marrow blast cells >= 10% and a Charlson comorbidity index >= 1 as 2 independent factors for efficacy. In conclusion, very-low-dose decitabine showed relatively good efficacy, good tolerance, and low medical cost in the treatment of intermediate-or high-risk MDS. Elderly patients with more than 1 complication or patients with a higher proportion of blast cells may be the most suitable candidates for this regimen. (C) 2017 S. Karger AG, Basel

基金：

语种：

被引次数：

WOS：

PubmedID：

中科院(CAS)分区：

出版当年[2016]版：

大类 | 4 区医学

小类 | 4 区血液学

最新[2025]版：

大类 | 4 区医学

小类 | 4 区血液学

JCR分区：

出版当年[2015]版：

Q4 HEMATOLOGY

最新[2023]版：

Q3 HEMATOLOGY

影响因子： 1.7 最新[2023版] 2.1 最新五年平均 1.053 出版当年[2015版] 0.923 出版当年五年平均 1.116 出版前一年[2014版] 1.205 出版后一年[2016版]

第一作者：

第一作者机构： [14]Peking Union Medical College Hospital, Beijing , China

通讯作者：

通讯机构： [14]Peking Union Medical College Hospital, Beijing , China [*1]Department of Hematology Peking Union Medical College Hospital, No. 1 Shuaifuyuan Dongcheng District, Beijing 100730 (China)

推荐引用方式(GB/T 7714)：

APA：

MLA：

相关文献

[1]VERY LOW-DOSE DECITABINE IS EFFECTIVE IN TREATING INTERMEDIATE OR HIGH RISK MYELODYSPLASTIC SYNDROME [2]Very Low-Dose Decitabine Is Effective in Treating Intermediate or High Risk Myelodysplastic Syndrome [3]Summary of animal models of myelodysplastic syndrome [4]骨髓增生异常综合征患者骨髓纤维化程度定量分析及其预后价值 [5]荧光原位杂交技术在骨髓增生异常综合征中的应用 [6]国产复方贝那普利/氢氯噻嗪治疗轻中度高血压的随机双盲多中心平行对照临床研究 [7]Clinical Efficacy Analysis of the Low-Dose Decitabine in Combination with Cytarabine, All-Trans Retinoic Acid and Granulocyte Colony-Stimulating Factor for Patients with MDS-EB [8]较低危骨髓增生异常综合征中难治性血细胞减少的治疗 [9]骨髓增生异常综合征红细胞免疫功能变化及其意义 [10]